Congrats to @blankbio_ on their $7.2M seed and strategic collab with PacBio! They're training foundation models on bulk RNA-seq data to help pharma teams design better clinical trials. Good drugs fail when their effect gets lost in patient variability, or when trials enroll patients whose biology won't respond. Blank Bio's models learn that heterogeneity to build prognostic and predictive biomarkers from tumor transcriptomes. https://blank.bio/seed-announcement